摘要
目的分析头孢噻肟钠联合培菲康治疗肝硬化自发性腹膜炎(spontaneous bacterial peritonitis,SBP)的临床疗效和不良反应。方法选取西安市第四医院就诊的84例肝硬化SBP患者,依据治疗方案不同分为:研究组41例,应用头孢噻肟钠联合培菲康治疗;对照组43例,仅应用头孢噻肟钠治疗。两组疗程均为14 d,比较两组患者临床疗效及不良反应的差异。结果与对照组相比,研究组的显效率、有效率及总有效率显著较高(P<0.05),发热、腹痛、腹胀、腹部压痛及腹水菌群等临床表现缓解时间明显较短(P<0.05),且肝功能衰竭、低血压性休克及病死率显著减少(P<0.05)。结论头孢噻肟钠联合培菲康治疗肝硬化SBP疗效显著,不良反应少。
Objective To analyze the clinical effect and side effect of cefotaxime sodium and bifid triple viable in treatment of spontaneous bacterial peritonitis （SBP） of liver cirrhosis. Methods 84 patients with SBP of liver cirrhosis in the Fourth Hospital of Xi＇an were divided into two groups： research group （41 cases, application with cefotaxime sodium and bifid triple viable） and control group （43 cases, application with cefotaxime sodium only） , based on distinct chemotherapies. The courses of treatment was both 14 days in two groups. The indexes of clinical effect and side effect were compared between two groups. Results Compared with control group, the excellence rate, effective rate and total effective rate in research group were higher （P 〈 0.05） , the remission time of clinical symptoms, such as fever, abdominal pain, abdominal distension, abdominal tenderness and intestinal flora in research group were shorter （P 〈 0.05 ）, and the occurrences of hepatic failure, hypotensive shock and mortality rate in research group were lower （P 〈 0.05 ）. Conclusion The combination of cefotaxime sodium and bifid triple viable is better effective, less side effects and better prognosis in treatment of SBP of liver cirrhosis.
出处
《胃肠病学和肝病学杂志》
CAS
2014年第2期205-207,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
头孢噻肟钠
双歧三联活菌
肝硬化
自发性腹膜炎
Cefotaxime sodium
Bifid triple viable
Liver cirrhosis
Spontaneous bacterial peritonitis
